Robert Scott was appointed Director of Arcutis Biotherapeutics, Inc. As of November 6, 2026, Arcutis Biotherapeutics, Inc. has reported 3 leadership change filings to the SEC under Item 5.02 of Form 8-K, from July 16, 2026 to October 28, 2026, naming 3 appointments and 1 departure (Form 8-K, October 28, 2026).
Who owns Arcutis Biotherapeutics, Inc.?
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Arcutis Biotherapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · In / out: In · Person: Robert Scott · Role: Director · 8-K, 2026-10-28
- · In / out: Out · Person: L. Todd Edwards · Effective: 2026-08-21 · 8-K, 2026-08-05
- · In / out: In · Person: Christopher Peetz · Role: Director · 8-K, 2026-07-16
Arcutis Biotherapeutics, Inc. reported changes in 3 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-07-16 to 2026-10-28. They name 4 people, with 3 appointments and 1 departure. Every row below is cited to the filing it comes from, and this page adds each new change as Arcutis Biotherapeutics, Inc. files it.
Also on the record for Arcutis Biotherapeutics, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| October 5, 2026 | Stake report, Schedule 13G/A, by BlackRock, Inc. | 14.1% of the class | 5%+ stakes | Source |
| August 14, 2026 | Stake report, Schedule 13G, by Polar Capital Holdings Plc | 5.28% of the class | 5%+ stakes | Source |
| August 7, 2026 | Stake report, Schedule 13G, by STATE STREET CORPORATION | 4.7% of the class | 5%+ stakes | Source |
| May 12, 2026 | Stake report, Schedule 13G, by STATE STREET CORPORATION | 5.1% of the class | 5%+ stakes | Source |
| May 8, 2026 | Stake report, Schedule 13G/A, by PRUDENTIAL FINANCIAL INC | 4.3% of the class | 5%+ stakes | Source |
| May 6, 2026 | Stake report, Schedule 13G/A, by Jennison Associates LLC | 4% of the class | 5%+ stakes | Source |
| March 26, 2026 | Stake report, Schedule 13G/A, by The Vanguard Group | — | 5%+ stakes | Source |
| February 13, 2026 | Stake report, Schedule 13G/A, by PRUDENTIAL FINANCIAL INC | 5.7% of the class | 5%+ stakes | Source |
| February 13, 2026 | Stake report, Schedule 13G/A, by Rubric Capital Management LP | 6.75% of the class | 5%+ stakes | Source |
| January 30, 2026 | Stake report, Schedule 13G/A, by Jennison Associates LLC | 5.5% of the class | 5%+ stakes | Source |
| October 6, 2025 | Stake report, Schedule 13G/A, by Jennison Associates LLC | 10.2% of the class | 5%+ stakes | Source |
| August 20, 2025 | Stake report, Schedule 13D/A, by Frazier Life Sciences VIII, L.P. | 7.5% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Arcutis Biotherapeutics, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Arcutis Biotherapeutics, Inc. and the records around it.
Arcutis Biotherapeutics, Inc. elsewhere on the record
- 5%+ stake filings Oct 2026
- Who owns it
Companies that share a holder
- Polar Capital Holdings Plc also filed stake reports on 3 other companies: Verastem, Inc. (Jul 2026), ENLIVEN THERAPEUTICS, INC. (Jun 2026), HAGERTY, INC. (Sep 2025)
- Jennison Associates LLC also filed stake reports on 14 other companies: LENDINGTREE INC (Oct 2026), PALVELLA THERAPEUTICS INC (Oct 2026), REZOLUTE INC (Oct 2026)
- PRUDENTIAL FINANCIAL INC also filed stake reports on 20 other companies: National Healthcare Properties, Inc. (Oct 2026), Neurogene Inc. (Oct 2026), PALVELLA THERAPEUTICS, INC. (Aug 2026)
Watch Arcutis Biotherapeutics, Inc.
Get an email when Arcutis Biotherapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Arcutis Biotherapeutics, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Arcutis Biotherapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Arcutis Biotherapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
15 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
The newest 12 of 13 records.
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-10-28 | In | Director | 8-K, 2026-10-28 | ||
| 2026-08-05 | Out | 2026-08-21 | 8-K, 2026-08-05 | ||
| 2026-08-05 | In | 8-K, 2026-08-05 | |||
| 2026-07-16 | In | Director | 8-K, 2026-07-16 |
Who leads Arcutis Biotherapeutics, Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Director: Robert Scott, appointed (filed 2026-10-28).
New leaders reset buying decisions — get the Full Report on Arcutis Biotherapeutics, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Director at Arcutis Biotherapeutics, Inc., with the record behind each one.
Find candidates like Director at Arcutis Biotherapeutics, Inc.Every change, in the filing's words
Appointed: Robert Scott, Director
On October 23, 2026, the Board of Directors (the "Board") of Arcutis Biotherapeutics, Inc. (the "Company") increased the authorized number of directors on the Board from ten to eleven directors and appointed Dr. Robert Scott as a new member of the Board and the Nominating and Corporate Governance Committee of the Board.
- Dr. Scott was appointed as a Class II director, with a term expiring at the Company's 2028 annual meeting of stockholders and until his successor is duly elected and qualified, or his earlier death, resignation, disqualification or removal.
- The Board determined that Dr. Scott qualifies as an independent director under the applicable rules and regulations of the Securities and Exchange Commission and the listing standards of The Nasdaq Stock Market LLC.
- Robert Scott, M.D., age 73, has served in various leadership positions in the global pharmaceuticals industry for several decades.
- Dr. Scott previously served as Chief Medical Officer and Head of Development of AbbVie Inc., a publicly traded global biopharmaceutical company, from April 2016 until his retirement in April 2020.
- Prior to AbbVie Inc., Dr. Scott served as Vice President, Global Development and Therapeutic Area Head at Amgen Inc., a publicly traded global biopharmaceutical company, from November 2010 to March 2016.
- In that role, he led the Cardiovascular, Metabolic, Nephrology, Neuroscience, Bone and Inflammation Therapeutic Areas and was Head of the Amgen Development Design Center.
- Before Amgen Inc., Dr. Scott served as Chief Medical Officer and Head of Development of Cerenis Therapeutics, a then-privately held pharmaceutical company, from January 2008 to May 2010.
Departing: L. Todd Edwards, effective 2026-08-21
On July 31, 2026, L. Todd Edwards notified Arcutis Biotherapeutics, Inc. (the "Company") of his decision to resign as chief commercial officer of the Company, effective as of August 21, 2026.
Appointed: Robert Lisicki
The Company has commenced a search for a permanent chief commercial officer and has appointed Robert Lisicki as interim executive vice president, starting August 17, 2026, and as interim chief commercial officer, effective upon Mr. Edwards' departure from the Company on August 21, 2026.
- Mr. Edwards is pursuing an external opportunity and his resignation is not due to any disagreement with the Company.
- Mr. Lisicki, 59, most recently served as chief executive officer and a director at Zura Bio Limited from April 2024 to January 2026, and was previously their president and chief operating officer from January 2024.
- Mr. Lisicki is an experienced executive leader with a career spanning over 30 years in the biopharmaceutical industry.
- Mr. Lisicki has served on the board of Cadrenal Therapeutics, Inc. since July 2023.
- He previously served as the chief executive officer and a member of the board of directors of InCarda Therapeutics, Inc. from October 2022 to April 2023, where he remained as a consultant until June 2023.
- Mr. Lisicki previously served as the chief commercial officer at Arena Pharmaceuticals, Inc. from October 2018 until its acquisition by Pfizer in March 2022.
- At Arena Pharmaceuticals, Inc., Mr. Lisicki built the company's global commercial infrastructure and contributed to its mergers and acquisitions activities totaling nearly $8.0 billion.
- Prior to Arena Pharmaceuticals, Inc., Mr. Lisicki served as vice president and general manager of inflammation and cardiovascular at Regeneron Pharmaceuticals, Inc. In this dual role, he led both commercial and developmental initiatives.
Appointed: Christopher Peetz, Director
On July 15, 2026, the Board of Directors (the "Board") of Arcutis Biotherapeutics, Inc. (the "Company") increased the authorized number of directors on the Board from nine to ten directors and appointed Mr. Christopher Peetz as a new member of the Board.
- Mr. Peetz was appointed as a Class III director, with a term expiring at the Company's 2029 annual meeting of stockholders or until his successor is duly elected and qualified, or his earlier death, resignation, disqualification or removal.
- The Board determined that Mr. Peetz qualifies as an independent director under the applicable rules and regulations of the Securities and Exchange Commission and the listing standards of The Nasdaq Stock Market LLC.
- Mr. Peetz has not been appointed to any committee of the Board.
- Mr. Peetz is a co-founder of Mirum Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, where he has served as Chief Executive Officer since March 2019 and as President from November 2018 to January 2024.
- Prior to Mirum Pharmaceuticals, Inc., Mr. Peetz served as Chief Executive Officer of Flashlight Therapeutics, Inc., a biotechnology company, from May 2017 to May 2019.
- He also previously served as Chief Financial Officer and head of corporate development at Tobira Therapeutics, Inc., a publicly-traded biotechnology company acquired by Allergan plc. in November 2016, from May 2014 to December 2016.
- Prior to joining Tobira Therapeutics, Inc, Mr. Peetz served as Vice President, Finance and Corporate Development of Jennerex Biotherapeutics, Inc., a biopharmaceutical company.
Tools for this story
Each opens in a new tab, filled in for Arcutis Biotherapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.